Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data
Open Access
- 9 May 2011
- journal article
- research article
- Published by Springer Nature in Malaria Journal
- Vol. 10 (1) , 116
- https://doi.org/10.1186/1475-2875-10-116
Abstract
Background: As a result of widespread chloroquine and sulphadoxine-pyrimethamine (SP) resistance, 90% of sub-Saharan African countries had adopted policies of artemisinin-based combination therapy (ACT) for treatment of uncomplicated malaria by 2007. In Malawi, cessation of chloroquine use was followed by the re-emergence of chloroquine-susceptible malaria. It was expected that introduction of ACT would lead to a return in chloroquine susceptibility throughout Africa, but this has not yet widely occurred. This observation suggests that there is continuing use of ineffective anti-malarials in Africa and that persistent chloroquine-resistant malaria is due to ongoing drug pressure despite national policy changes. Methods: To estimate drug use on a national level, 2006-2007 Demographic Health Survey and Multiple Indicator Cluster Survey data from 21 African countries were analysed. Resistance data were compiled by systematic review of the published literature on the prevalence of the Plasmodium falciparum chloroquine resistance transporter polymorphism at codon 76, which causes chloroquine resistance. Results: Chloroquine was the most common anti-malarial used according to surveys from 14 of 21 countries analysed, predominantly in West Africa. SP was most commonly reported in two of 21 countries. Among eight countries with longitudinal molecular resistance data, the four countries where the highest proportion of children treated for fever received chloroquine (Uganda, Burkina Faso, Guinea Bissau, and Mali) also showed no significant declines in the prevalence of chloroquine-resistant infections. The three countries with low or decreasing chloroquine use among children who reported fever treatment (Malawi, Kenya, and Tanzania) had statistically significant declines in the prevalence of chloroquine resistance. Conclusions: This study demonstrates that in 2006-2007, chloroquine and SP continued to be used at high rates in many African countries. In countries reporting sustained chloroquine use, chloroquine-resistant malaria persists. In contrast, a low level of estimated chloroquine use is associated with a declining prevalence of chloroquine resistance.Keywords
This publication has 62 references indexed in Scilit:
- Return of Chloroquine‐Susceptible Falciparum Malaria in Malawi Was a Reexpansion of Diverse Susceptible ParasitesThe Journal of Infectious Diseases, 2010
- A molecular map of chloroquine resistance in MaliFEMS Immunology & Medical Microbiology, 2010
- Artemisinin Resistance inPlasmodium falciparumMalariaNew England Journal of Medicine, 2009
- Genetic structure of Plasmodium falciparum populations between lowland and highland sites and antimalarial drug resistance in Western KenyaInfection, Genetics and Evolution, 2009
- Decreasing Efficacy of Antimalarial Combination Therapy in Uganda Is Explained by Decreasing Host Immunity Rather than Increasing Drug ResistanceThe Journal of Infectious Diseases, 2009
- In Vivo Selection ofPlasmodium falciparumParasites Carrying the Chloroquine-SusceptiblepfcrtK76 Allele after Treatment with Artemether-Lumefantrine in AfricaThe Journal of Infectious Diseases, 2009
- Efficacy of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria: revisiting molecular markers in an area of emerging AQ and SP resistance in MaliMalaria Journal, 2009
- Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in NigerMalaria Journal, 2009
- Evidence of Artemisinin-Resistant Malaria in Western CambodiaNew England Journal of Medicine, 2008
- Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum mdr1 Gene in Tanzanian Children Treated for Uncomplicated MalariaAntimicrobial Agents and Chemotherapy, 2007